Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021

This industry research report identifies Bristol-Myers Squibb, Novartis, Pfizer, and F. Hoffmann-La Roche as the key vendors in the global graft vs host disease (GVHD) treatment market. This industry research report also presents a competitive analysis of the market by disease type (acute GVCD and chronic GVCD) and by geography (the Americas, APAC, and EMEA). 

Overview of the global graft vs host disease (GVHD) treatment market

Research analysis of the global GVHD treatment market identifies the growing number of organ transplantation cases as one of the major factors that will have a positive impact on the growth of the market. The rise in chronic diseases across the globe has led to the growth in the need for organ transplantation. It has been observed that in 2015, the US witnessed more than 30,000 organ transplants cases, which has increased about 5% when compared to the previous year. Similarly, countries such as Australia also witnesses increasing cases of organ transplantation. This rising number of organ transplants will subsequently augment the growth prospects of the GVHD treatment market. According to the graft versus host disease GVHD treatment industry analysis, this market will grow at a CAGR of more than 7% by 2021.

The increasing applications of bone marrow transplant are one of the major graft versus host disease market trends which will gain traction in the market growth during the next four years. Bone marrow that was widely used only in the treatment of cancer has found significance in the treatment of various cardiovascular, autoimmune, neurological, and Myelodysplastic diseases. According to the University of Washington School of Medicine in the US, clinical trials carried out by injecting bone marrow cells directly into the heart of individuals with ischemic cardiomyopathy resulted in considerable improvements. Such trials will increase the number of bone marrow transplantations in the coming years, which will subsequently drive the growth of the GVHD market.

Competitive landscape and key vendors

The market has the presence of several large and small vendors and appears to be highly fragmented and competitive. The vendors in the market are forming pricing strategies to sustain the increasing competition. Additionally, the vendors are investing heavily in R&D to launch effective drugs and are also forming strategic alliances to strengthen their market presence. For instance, Bristol-Myers Squibb recently formed a strategic alliance with Nordic Bioscience for technological advancement.

The leading vendors in the market are 

• Bristol-Myers Squibb
• Novartis
• Pfizer
• F. Hoffmann-La Roche

The other prominent vendors in the market are Abbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Baxter, Caladrius, Cellular Biomedicine Group, Cipla, Eisai, Eli Lilly, GlaxoSmithKline, Glenmark, Helsinn Healthcare, Heron Therapeutics, Incyte Corporation, IPCA Laboratories, Kadmon Holdings, Lupin, Osiris Therapeutics, RedHill, Sanofi, Shire, Sun Pharmaceutical Industries, Takeda Pharmaceutical, and ViaCyte.

Segmentation by disease type and analysis of the GVHD treatment market

• Acute GVCD
• Chronic GVCD

During 2016, the acute GVCD segment accounted for the major shares for this market. This is mainly due to the increasing prevalence of various diseases including cancer that led to the growth in the number of organ transplantations. Owing to factors such as the rise in awareness, better diagnosis, and early approach to treatment, the prevalence of acute GVHD is high in the developed countries.

Geographical segmentation and analysis of the GVHD treatment market

• Americas
• APAC
• EMEA

This market study estimates that in terms of geographic regions, the Americas will be the major revenue contributor to the GVHD treatment market by 2021. The increasing number of transplantation procedures and the growing healthcare infrastructure will fuel the growth prospects of the market in this region. Moreover, the increasing cases of organ failures due to the unhealthy lifestyle and dietary habits of the people and the approvals of new drugs for the treatment of GVHD, will also drive the market’s growth in this region.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global graft vs host disease (GVHD) treatment market?
• What are the key market trends impacting the growth of the global graft vs host disease (GVHD) treatment market?
• What are the challenges to market growth?
• Who are the key vendors in the global graft vs host disease (GVHD) treatment market?
• What are the market opportunities and threats faced by the vendors in the global graft vs host disease (GVHD) treatment market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global graft vs host disease (GVHD) treatment market?

Technavio also offers customization on reports based on specific client requirement.